A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset™ or placebo

BACKGROUND: Cycloset™ is a quick-release formulation of bromocriptine mesylate, a dopamine agonist, which in animal models of insulin resistance and type 2 diabetes acts centrally to reduce resistance to insulin- mediated suppression of hepatic glucose output and tissue glucose disposal. In such ani...

Descripción completa

Detalles Bibliográficos
Autores principales: Scranton, Richard E, Gaziano, J Michael, Rutty, Dean, Ezrokhi, Michael, Cincotta, Anthony
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924849/
https://www.ncbi.nlm.nih.gov/pubmed/17592632
http://dx.doi.org/10.1186/1472-6823-7-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1924849/
https://www.ncbi.nlm.nih.gov/pubmed/17592632
http://dx.doi.org/10.1186/1472-6823-7-3

Ejemplares similares